Stigma, risks, and benefits of medicinal cannabis use among Australians with cancer

dc.contentTexten_US
dc.contributor.authorLoyer, Jessica
dc.contributor.authorMorris, Julia N.
dc.contributor.authorBlunk, Jason
dc.date.accessioned2024-08-14T01:40:27Z
dc.date.available2024-08-14T01:40:27Z
dc.date.issued2024-03
dc.descriptionThe library currently does not have access to the full text of this article.en_US
dc.description.abstractPurpose People with cancer who use medicinal cannabis do so despite risks associated with limited clinical evidence, legalities, and stigma. This study investigated how Australians with cancer rationalise their medicinal cannabis use despite its risks. Methods Ten adults (5 males and 5 females; mean age of 53.3) who used cannabis medicinally for their cancer were interviewed in 2021–2022 about how they used and accessed the substance, attitudes and beliefs underpinning their use, and conversations with others about medicinal cannabis. Results Participants had cancer of the bowel, skin, oesophagus, stomach, thyroid, breast, and Hodgkin lymphoma for which they were receiving treatment (n = 5) or under surveillance (n = 5), with most (n = 6) encountering metastatic disease. Cannabis was used to treat a variety of cancer-related symptoms such as pain, poor sleep, and low mood. Cannabis was perceived as natural and thus less risky than pharmaceuticals. Participants legitimised their medicinal cannabis use by emphasising its natural qualities and distancing themselves from problematic users or riskier substances. Cost barriers and a lack of healthcare professional communication impeded prescription access. Similarly, participants navigated medicinal cannabis use independently due to a lack of guidance from healthcare professionals. Conclusion Findings highlight the need for robust data regarding the harms and efficacy of medicinal cannabis and dissemination of such information among healthcare professionals and to patients who choose to use the substance. Ensuring healthcare professionals are equipped to provide non-judgmental and evidence-based guidance may mitigate potential safety and legal risks.en_US
dc.identifier.citationMorris, J.N., Loyer, J. & Blunt, J. (2024). Stigma, risks, and benefits of medicinal cannabis use among Australians with cancer. Supportive Care in Cancer, 32, Article 252. https://doi.org/10.1007/s00520-024-08439-wen_US
dc.identifier.doihttps://doi.org/10.1007/s00520-024-08439-wen_US
dc.identifier.issn1433-7339
dc.identifier.journalTitleSupportive Care in Canceren_US
dc.identifier.urihttps://link.springer.com/article/10.1007/s00520-024-08439-wen_US
dc.identifier.urihttps://dspace.angliss.edu.au/handle/20.500.12270/581
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.infacultyHigher Educationen_US
dc.rights.holderSpringer Natureen_US
dc.subjectCannabis -- Therapeutic use -- Australiaen_US
dc.titleStigma, risks, and benefits of medicinal cannabis use among Australians with canceren_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections

William Angliss Institute is the Government endorsed specialist training provider for the foods, tourism, hospitality and events industries. Over more than 85 years we have earned a strong global reputation for the delivery of innovative higher education, training solutions and consultancy services to clients across Australia and abroad. Read more...